In this single institution cross-sectional analysis of 589 chest CTA’s ordered for suspected PE, only 9% had a PE, 33% had other findings to explain the symptoms, and 24% had an incidental finding that required follow up (primarily a new nodule or new adenopathy). Given that almost a quarter of patients that receive a CTA for PE will have an incidental finding requiring follow-up, systematic procedures for ensuring this follow-up will be required (abstract).
I am coming up on my two year anniversary. Not my wedding anniversary (soon to be 15 years – thanks Maia!), but two years since I joined the ranks of the patients. It was two years ago this week that my day was interrupted by a page from my internist saying, “I don’t know how […]
As you can see, no glamour shots for this month’s post. I knew it would come at some point, and my first hospitalization related to my CLL came in a big way in mid-July. Given my interest in global health, it was only fitting that I managed to get sick while out of the […]
This large multicenter trial randomized patients with acute VTE to apixaban (10mg BID for 1 week, followed by 5mg BID for 6 months) versus conventional therapy (lovenox-warfarin). The primary outcome was similar between groups (symptomatic VTE or death related to VTE), but major and minor bleeding occurred significantly less often with apixaban. Apixaban is a […]